{"created":"2024-11-22T06:26:37.282277+00:00","id":2008037,"links":{},"metadata":{"_buckets":{"deposit":"956114e9-481a-47bb-b491-897b874b7a00"},"_deposit":{"created_by":7,"id":"2008037","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2008037"},"status":"published"},"_oai":{"id":"oai:tokushima-u.repo.nii.ac.jp:02008037","sets":["1713853213384:1713853295607"]},"author_link":["309"],"control_number":"2008037","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-04-29","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"1594","bibliographicPageStart":"1585","bibliographicVolumeNumber":"7","bibliographic_titles":[{"bibliographic_title":"ESC Heart Failure","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aims\nLittle is known about the impact of sodium glucose co‐transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on changes in N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), in that patient population.\nMethods and results\nPatients with T2D and stable CHF, randomized to receive canagliflozin 100 mg or glimepiride (starting‐dose: 0.5 mg), were examined using the primary endpoint of non‐inferiority of canagliflozin vs. glimepiride, defined as a margin of 1.1 in the upper limit of the two‐sided 95% confidence interval (CI) for the group ratio of percentage change in NT‐proBNP at 24 weeks. Data analysis of 233 patients showed mean left ventricular ejection fraction (LVEF) at randomization was 57.6 ± 14.6%, with 71% of patients having a preserved LVEF (≥50%). Ratio of NT‐proBNP percentage change was 0.48 (95% CI, −0.13 to 1.59, P = 0.226) and therefore did not meet the prespecified non‐inferiority margin. However, NT‐proBNP levels did show a non‐significant trend lower in the canagliflozin group [adjusted group difference; −74.7 pg/mL (95% CI, −159.3 to 10.9), P = 0.087] and also in the subgroup with preserved LVEF [−58.3 (95% CI, −127.6 to 11.0, P = 0.098]).\nConclusions\nThis study did not meet the predefined primary endpoint of changes in NT‐proBNP levels, with 24 weeks of treatment with canagliflozin vs. glimepiride. Further research is warranted to determine whether patients with heart failure with preserved ejection fraction, regardless of diabetes status, could potentially benefit from treatment with SGLT2 inhibitors.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"The Heart Failure Association of the European Society of Cardiology","subitem_publisher_language":"en"},{"subitem_publisher":"Wiley","subitem_publisher_language":"en"}]},"item_10001_rights_15":{"attribute_name":"権利情報","attribute_value_mlt":[{"subitem_rights":"This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.","subitem_rights_language":"en"}]},"item_10001_source_id_9":{"attribute_name":"収録物ID","attribute_value_mlt":[{"subitem_source_identifier":"20555822","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1715043197608":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access"}]},"item_1722929371688":{"attribute_name":"出版社版DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_language":"ja","subitem_relation_name_text":"10.1002/ehf2.12707"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1002/ehf2.12707","subitem_relation_type_select":"DOI"}}]},"item_1723180141928":{"attribute_name":"EID","attribute_value_mlt":[{"subitem_identifier_type":"URI","subitem_identifier_uri":"366094"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"タナカ, アツシ","creatorNameLang":"ja"},{"creatorName":"タナカ, アツシ","creatorNameLang":"ja-Kana"},{"creatorName":"Tanaka, Atsushi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ヒサウチ, イタル","creatorNameLang":"ja"},{"creatorName":"ヒサウチ, イタル","creatorNameLang":"ja-Kana"},{"creatorName":"Hisauchi, Itaru","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"タグチ, イサオ","creatorNameLang":"ja"},{"creatorName":"タグチ, イサオ","creatorNameLang":"ja-Kana"},{"creatorName":"Taguchi, Isao","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"セザイ, アキラ","creatorNameLang":"ja"},{"creatorName":"セザイ, アキラ","creatorNameLang":"ja-Kana"},{"creatorName":"Sezai, Akira","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"トヨダ, シゲル","creatorNameLang":"ja"},{"creatorName":"トヨダ, シゲル","creatorNameLang":"ja-Kana"},{"creatorName":"Toyoda, Shigeru","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"トミヤマ, ヒロフミ","creatorNameLang":"ja"},{"creatorName":"トミヤマ, ヒロフミ","creatorNameLang":"ja-Kana"},{"creatorName":"Tomiyama, Hirofumi","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"佐田, 政隆","creatorNameLang":"ja"},{"creatorName":"サタ, マサタカ","creatorNameLang":"ja-Kana"},{"creatorName":"Sata, Masataka","creatorNameLang":"en"}],"familyNames":[{"familyName":"佐田","familyNameLang":"ja"},{"familyName":"サタ","familyNameLang":"ja-Kana"},{"familyName":"Sata","familyNameLang":"en"}],"givenNames":[{"givenName":"政隆","givenNameLang":"ja"},{"givenName":"マサタカ","givenNameLang":"ja-Kana"},{"givenName":"Masataka","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"309","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"173932/profile-ja.html","nameIdentifierScheme":"徳島大学 教育研究者総覧","nameIdentifierURI":"http://pub2.db.tokushima-u.ac.jp/ERD/person/173932/profile-ja.html"},{"nameIdentifier":"80345214","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?qm=80345214"}]},{"creatorNames":[{"creatorName":"ウエダ, シンイチロウ","creatorNameLang":"ja"},{"creatorName":"ウエダ, シンイチロウ","creatorNameLang":"ja-Kana"},{"creatorName":"Ueda, Shinichiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"オヤマ, ジュンイチ","creatorNameLang":"ja"},{"creatorName":"オヤマ, ジュンイチ","creatorNameLang":"ja-Kana"},{"creatorName":"Oyama, Jun-ichi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"キタカゼ, マサフミ","creatorNameLang":"ja"},{"creatorName":"キタカゼ, マサフミ","creatorNameLang":"ja-Kana"},{"creatorName":"Kitakaze, Masafumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ムロハラ, トヨアキ","creatorNameLang":"ja"},{"creatorName":"ムロハラ, トヨアキ","creatorNameLang":"ja-Kana"},{"creatorName":"Murohara, Toyoaki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ノデ, コウイチ","creatorNameLang":"ja"},{"creatorName":"ノデ, コウイチ","creatorNameLang":"ja-Kana"},{"creatorName":"Node, Koichi","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"ehf_7_4_1585.pdf","filesize":[{"value":"736 KB"}],"format":"application/pdf","licensetype":"license_3","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://tokushima-u.repo.nii.ac.jp/record/2008037/files/ehf_7_4_1585.pdf"},"version_id":"166d6c31-7b9e-48df-b4d8-9eecdc777dbd"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Type 2 diabetes","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Heart failure","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"SGLT2 inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"NT-proBNP","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Non-inferiority","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Glimepiride","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure : a randomized trial (CANDLE)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure : a randomized trial (CANDLE)","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"7","path":["1713853295607"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-12-21"},"publish_date":"2020-12-21","publish_status":"0","recid":"2008037","relation_version_is_last":true,"title":["Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure : a randomized trial (CANDLE)"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2025-01-29T06:58:45.714476+00:00"}